Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

750 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma.
Kinoshita R, Ishibashi M, Handa H, Sasaki M, Imai Y, Tanaka N, Ito S, Sunakawa-Kii M, Kaito Y, Asayama T, Komatsu N, Tanaka J, Odajima T, Sugimori H, Yamaguchi H, Inokuchi K, Tamura H. Kinoshita R, et al. Among authors: inokuchi k. Exp Hematol. 2023 May;121:38-47.e2. doi: 10.1016/j.exphem.2023.01.006. Epub 2023 Feb 14. Exp Hematol. 2023. PMID: 36796620
Clinical impact of serum soluble SLAMF7 in multiple myeloma.
Ishibashi M, Soeda S, Sasaki M, Handa H, Imai Y, Tanaka N, Tanosaki S, Ito S, Odajima T, Sugimori H, Asayama T, Sunakawa M, Kaito Y, Kinoshita R, Kuribayashi Y, Onodera A, Moriya K, Tanaka J, Tsukune Y, Komatsu N, Inokuchi K, Tamura H. Ishibashi M, et al. Among authors: inokuchi k. Oncotarget. 2018 Oct 5;9(78):34784-34793. doi: 10.18632/oncotarget.26196. eCollection 2018 Oct 5. Oncotarget. 2018. PMID: 30410677 Free PMC article.
Immunotherapy for Multiple Myeloma.
Tamura H, Ishibashi M, Sunakawa M, Inokuchi K. Tamura H, et al. Among authors: inokuchi k. Cancers (Basel). 2019 Dec 12;11(12):2009. doi: 10.3390/cancers11122009. Cancers (Basel). 2019. PMID: 31842518 Free PMC article. Review.
SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma.
Ishibashi M, Takahashi R, Tsubota A, Sasaki M, Handa H, Imai Y, Tanaka N, Tsukune Y, Tanosaki S, Ito S, Asayama T, Sunakawa M, Kaito Y, Kuribayashi-Hamada Y, Onodera A, Moriya K, Komatsu N, Tanaka J, Odajima T, Sugimori H, Inokuchi K, Tamura H. Ishibashi M, et al. Among authors: inokuchi k. Mol Cancer Res. 2020 Apr;18(4):632-643. doi: 10.1158/1541-7786.MCR-19-0391. Epub 2020 Jan 23. Mol Cancer Res. 2020. PMID: 31974290
PD-L1-PD-1 Pathway in the Pathophysiology of Multiple Myeloma.
Tamura H, Ishibashi M, Sunakawa-Kii M, Inokuchi K. Tamura H, et al. Among authors: inokuchi k. Cancers (Basel). 2020 Apr 10;12(4):924. doi: 10.3390/cancers12040924. Cancers (Basel). 2020. PMID: 32290052 Free PMC article. Review.
750 results